Immune Checkpoint Inhibitor-Associated Uveitis: Predictors and Survival Impact
In 5966 patients treated with immune checkpoint inhibitors, uveitis was rare (0.49%) but linked to combination therapy, greater cumulative exposure, and prior uveitis. Uveitis occurrence was correlated with longer survival, suggesting heightened systemic immune activation.
Authors
- Elizabeth Hutchins (ORCID: https://orcid.org/0000-0003-2543-0798)
- En‐Hua Yang (ORCID: https://orcid.org/0000-0001-6066-8254)
- Edmund Yik Kong Tsui (ORCID: https://orcid.org/0000-0001-7532-9191)
- Ashley F. Stein-Merlob (ORCID: https://orcid.org/0000-0001-6261-6431)
- Leila Chew (ORCID: https://orcid.org/0000-0002-2779-5953)
- Jeffrey Feng (ORCID: https://orcid.org/0000-0002-6927-5200)
- Melissa G. Lechner (ORCID: https://orcid.org/0000-0002-4744-6566)
Institutions
- University of California, Los Angeles (US)
- UCLA Health (US)
- Doheny Eye Institute (US)
- Los Angeles Medical Center (US)
- Southern California Eye Institute (US)
Publication Details
- Journal
- Ophthalmology Retina
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1016/j.oret.2025.11.001
- Citations
- 1
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 1.71